4593 Healios KK
- 200
- +3+1.52%
Healios KK News
Healios KK: Milestone Achieved Pursuant to Joint Research Agreement with AND medical and Projected Demand for Culture Supernatant
Healios KK: Notice of milestone achievement and demand forecast based on a joint research agreement with AND Medical for the utilization of culture supernatants
Healios KK: Decision to Apply for Conditional and Time-Limited Approval for ARDS in Japan and ARDS Development Strategy Update
Healios KK: Determination and development strategy for implementing conditions and time-limited approval applications for ARDS therapeutics in Japan
Healios KK: Rescheduling of Conclusion of Development and Commercialization Agreement of MultiStem for ARDS in Japan with Nobelpharma
Healios KK: Notice of further extension of the planned date for concluding a development and sales partnership agreement with Nobel Pharma - Development and sales partnership for ARDS therapeutics in Japan
Healios KK: Agreement with the FDA on Pivotal, Global Phase 3 “REVIVE-ARDS” Clinical Trial
Healios KK: Agreement with the US FDA regarding ARDS global phase 3 trial design
Healios KK: Announcement of eNK cell research results at the 5th Annual Meeting of the Japanese Society of Asbestos and Mesothelioma
Healios KK: Share Transfer Report Relating to Third-Party Allocation (New Shares)
Healios KK: Report of transfer of new shares for third-party allotment.
Healios KK: Announcements of individual stocks regarding the presentation of research results on eNK cells at the 83rd Japanese Cancer Association annual meeting.
Healios KK: Announcements of individual stocks regarding the recording of financial income and financial expenses.
Healios KK: Financial results for the second quarter of 2024.
Healios KK: Development plan for Acute Respiratory Distress Syndrome (ARDS).
Healios KK: About future plans for development of ARDS treatment drugs.
Healios KK: The first patient registered for the clinical study of RPE tears using RPE cells derived from the same iPS cells (HLCR011).
Healios KK: Announcements of individual stocks: Subject recruitment has started for clinical trials targeting the macular hole using iPS-derived retinal pigment epithelial cells (HLCR011).
Healios KK: Academic paper on Helios UDC in stem cell research and treatment.
Healios KK: An article on Helios UDC was published in Stem Cell Research and Therapy.
Analysis
Price Target
No Data
No Data